Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8797 |
High Similarity |
NPD5124 |
Phase 1 |
0.8797 |
High Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.874 |
High Similarity |
NPD422 |
Phase 1 |
0.8623 |
High Similarity |
NPD1652 |
Phase 2 |
0.8433 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.8151 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8015 |
Intermediate Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7933 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7899 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.7895 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7883 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7852 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7843 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.784 |
Intermediate Similarity |
NPD290 |
Approved |
0.784 |
Intermediate Similarity |
NPD1358 |
Approved |
0.7838 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7823 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7823 |
Intermediate Similarity |
NPD9697 |
Approved |
0.7817 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7812 |
Intermediate Similarity |
NPD7843 |
Approved |
0.78 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7794 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7793 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7793 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7793 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7786 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7786 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7778 |
Intermediate Similarity |
NPD2684 |
Approved |
0.777 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.777 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7762 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7761 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.776 |
Intermediate Similarity |
NPD3134 |
Approved |
0.773 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7698 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7692 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7674 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7655 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7655 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7647 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7643 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7643 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7639 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7634 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7632 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7626 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7613 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7606 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7603 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7591 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7586 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7586 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7586 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7586 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7574 |
Intermediate Similarity |
NPD9717 |
Approved |
0.7566 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7556 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7551 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7548 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7548 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7535 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7533 |
Intermediate Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.7518 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7516 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD8158 |
Clinical (unspecified phase) |
0.7484 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7484 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7481 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7467 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7467 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7465 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7448 |
Intermediate Similarity |
NPD4308 |
Phase 3 |
0.7448 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7447 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7429 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7419 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7415 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7413 |
Intermediate Similarity |
NPD1240 |
Approved |
0.741 |
Intermediate Similarity |
NPD3267 |
Approved |
0.741 |
Intermediate Similarity |
NPD1203 |
Approved |
0.741 |
Intermediate Similarity |
NPD3266 |
Approved |
0.7407 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7407 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7368 |
Intermediate Similarity |
NPD920 |
Approved |
0.7365 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7357 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7355 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7353 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7343 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7333 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD6667 |
Approved |
0.7333 |
Intermediate Similarity |
NPD6666 |
Approved |
0.7324 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.731 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7301 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7292 |
Intermediate Similarity |
NPD4307 |
Phase 2 |
0.7292 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7285 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7285 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7273 |
Intermediate Similarity |
NPD1048 |
Approved |
0.7261 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.725 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7248 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7239 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7239 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7237 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7237 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7234 |
Intermediate Similarity |
NPD1019 |
Discontinued |
0.723 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.723 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.723 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.723 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.723 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.723 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7229 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7218 |
Intermediate Similarity |
NPD1241 |
Discontinued |
0.7215 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7211 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7206 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7206 |
Intermediate Similarity |
NPD1894 |
Discontinued |
0.7197 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7197 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7195 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7192 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7183 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7183 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7174 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.7171 |
Intermediate Similarity |
NPD1511 |
Approved |
0.717 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7169 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7165 |
Intermediate Similarity |
NPD846 |
Approved |
0.7165 |
Intermediate Similarity |
NPD940 |
Approved |
0.7163 |
Intermediate Similarity |
NPD6362 |
Approved |
0.7162 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7162 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7162 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7152 |
Intermediate Similarity |
NPD2415 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7143 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7143 |
Intermediate Similarity |
NPD3685 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7125 |
Intermediate Similarity |
NPD919 |
Approved |
0.7124 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7123 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7123 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7117 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7117 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7117 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7117 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7108 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7101 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7101 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7083 |
Intermediate Similarity |
NPD3179 |
Approved |
0.7083 |
Intermediate Similarity |
NPD3180 |
Approved |
0.7078 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7071 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7066 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7059 |
Intermediate Similarity |
NPD7837 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD6032 |
Approved |
0.7044 |
Intermediate Similarity |
NPD4288 |
Approved |
0.7042 |
Intermediate Similarity |
NPD987 |
Approved |
0.7039 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7037 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7034 |
Intermediate Similarity |
NPD411 |
Approved |
0.7034 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7025 |
Intermediate Similarity |
NPD37 |
Approved |
0.7024 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7024 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7021 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7021 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7021 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7015 |
Intermediate Similarity |
NPD821 |
Approved |
0.7013 |
Intermediate Similarity |
NPD3536 |
Discontinued |
0.7013 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7013 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7013 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7007 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7007 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7006 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.6994 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6993 |
Remote Similarity |
NPD5647 |
Approved |
0.6993 |
Remote Similarity |
NPD3690 |
Phase 2 |
0.6993 |
Remote Similarity |
NPD3691 |
Phase 2 |
0.6988 |
Remote Similarity |
NPD7286 |
Phase 2 |
0.6981 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.698 |
Remote Similarity |
NPD5588 |
Approved |
0.698
|
Remote Similarity |
NPD5960 |
Phase 3 |